Full Press Release Details
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE Setmelanotide Injection for Weight Management in Bardet Biedl Syndrome or Genetically confirmed Biallelic POMC P.
RYTM
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE Setmelanotide Injection for Weight Management in Bardet Biedl Syndrome or Genetically confirmed Biallelic POMC P
Key Takeaway: Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE Setmelanotide Injection for Weight Management in Bardet Biedl Syndrome or Genetically confirmed Biallelic POMC P